The Ireland-headquartered drugmaker Shire (LSE: SHP) was trading 2% higher on Tuesday after announcing that the US Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for prucalopride as a potential once-daily treatment option for chronic idiopathic constipation (CIC) in adults.
Prucalopride, a high affinity, selective serotonin type 4 (5 HT4) receptor agonist, is a gastrointestinal prokinetic agent that stimulates colonic peristalsis, increasing bowel motility.
"Today’s acceptance of the NDA reinforces the breadth and depth of Shire’s capabilities in gastrointestinal conditions"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze